Biomarker Work Needs To Start Early In Drug Development Programs, US FDA Says

 
• By Sue Sutter
  
Budding tree
The earlier the better when it comes to biomarker work in a drug development program. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D